MIRA Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- MIRA Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- MIRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001904286
Board of directors
-
Bradley Kroenig · DirectorSince 2023
-
Brian Frederick Daly · DirectorSince 2023
-
Christopher C. Chapman Jr. · Director · Executive ChairmanSince 2023
-
Christos Nicholoudis · DirectorSince 2023
-
David C. Vorhoff · DirectorSince 2023
-
Denil Nanji Shekhat · DirectorSince 2024
-
Edward Clouston MacPherson · DirectorSince 2024
-
Erez Aminov · Director · Chief Executive OfficerSince 2023
-
Giudice Matthew Paul Del · DirectorSince 2024
-
Hugh McColl III · DirectorSince 2023
-
Matthew Pratt Whalen · DirectorSince 2024
-
Michael Allen Jerman · DirectorSince 2023
-
Talhia Tuck · DirectorSince 2023
Chief executives
Erez Aminov
· CEO and Director
Since August 2023
Board connections
11 of this board's directors also sit on 5 other boards.
- via Bradley Kroenig, Christopher C. Chapman Jr., Christos Nicholoudis, Edward Clouston MacPherson, Erez Aminov, Giudice Matthew Paul Del, Hugh McColl III, Matthew Pratt Whalen, Michael Allen Jerman and Talhia Tuck
- via Michael Allen Jerman
- via Christopher C. Chapman Jr.
- via Brian Frederick Daly
- via Hugh McColl III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,294,685
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 16, 2025 | Erez Aminov Director, Officer (CEO and Chairman) | Option exercise | +234,595 | $1.16 | $272,130 |
| Oct 16, 2025 | Erez Aminov Director, Officer (CEO and Chairman) | Option exercise | +379,000 | $0.84 | $318,360 |
| Oct 16, 2025 | Erez Aminov Director, Officer (CEO and Chairman) | Open-market sale | −613,595 | $2.11 | $1,294,685 |
| Oct 1, 2025 | Denil Nanji Shekhat Director | Grant or award | +22,378 | $1.35 | $30,210 |
| Oct 1, 2025 | Erez Aminov Director, Officer (Chief Executive Officer) | Grant or award | +2,685,456 | — | — |
| Aug 29, 2025 | Erez Aminov Director, Officer (Chief Executive Officer) | Grant or award | +62,500 | $1.37 | $85,625 |
| Mar 26, 2025 | Erez Aminov Director, Officer (CEO and Chairman) | Grant or award | +62,500 | $1.45 | $90,625 |
| Mar 26, 2025 | Erez Aminov Director, Officer (CEO and Chairman) | Grant or award | +62,500 | $1.45 | $90,625 |
| Nov 20, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market sale | −44,590 | $1.27 | $56,629 |
| Nov 19, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market sale | −55,410 | $1.39 | $77,020 |
| Aug 28, 2024 | McNulty Brian Patrick 10% owner | Open-market sale | −200,000 | $1.96 | $392,000 |
| May 21, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market purchase | +2,000 | $1.00 | $2,000 |
| May 21, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market purchase | +1,000 | $1.03 | $1,030 |
| May 21, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market purchase | +500 | $1.02 | $510 |
| May 21, 2024 | Erez Aminov Director, Officer (Chief Executive Officer) | Open-market purchase | +2,000 | $0.84 | $1,680 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.